AstraZeneca
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2009-12-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00984477
- Locations
- π¬π§
Research Site, Nottinghamshire, United Kingdom
Epidemiology of Schizophrenia in Bulgaria
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2010-02-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 440
- Registration Number
- NCT00984373
- Locations
- π§π¬
Research Site, Vidin, Bulgaria
Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia
Completed
- Conditions
- Chronic Heart Failure
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT00984529
- Locations
- ππ·
Research Site, Zagreb, Croatia
ππ·Reserach Site, Zabok, Croatia
Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2009-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT00984880
- Locations
- πΈπͺ
Research Site, Stockholm, Sweden
A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies
Phase 1
Completed
- Conditions
- Advanced Solid Malignancies
- Interventions
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2011-06-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00981721
- Locations
- π¨π³
Research Site, Hong Kong, Hong Kong, China
Non-interventional (NI) Study to Observe Efficacy and Usage of Quetiapine in Acute Episodes of Schizophrenia and as Maintenance Therapy Following Standard Clinical Practice in Croatia
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2011-01-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT00981123
- Locations
- ππ·
Research Site, Zagreb, Croatia
AZD8683 Single Ascending Dose Study
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 130
- Registration Number
- NCT00979849
- Locations
- πΊπΈ
Research Site, Philadelphia, Pennsylvania, United States
Evaluation of Diabetes Care at Austrian GPs
Terminated
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2010-08-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1513
- Registration Number
- NCT00979394
Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours
- First Posted Date
- 2009-09-17
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 95
- Registration Number
- NCT00979134
- Locations
- π¬π§
Research Site, Wolverhampton, United Kingdom
Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Part 1 - AZD2423 or PlaceboDrug: Part 2 - AZD2423Drug: Part 3 - AZD2423
- First Posted Date
- 2009-09-16
- Last Posted Date
- 2012-01-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 74
- Registration Number
- NCT00977626
- Locations
- π¬π§
Research Site, Harrow, United Kingdom